A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
about
multiClust: An R-package for Identifying Biologically Relevant Clusters in Cancer Transcriptome ProfilesDistinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcomeEnigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A'Omic approaches to preventing or managing metastatic breast cancerGenome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancerClinical and multiple gene expression variables in survival analysis of breast cancer: Analysis with the hypertabastic survival modelAn 18-gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancerExpression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer.Database integration of 4923 publicly-available samples of breast cancer molecular and clinical data.Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samplesInvestigating the prediction ability of survival models based on both clinical and omics data: two case studies.IDEA: Integrated Drug Expression Analysis-Integration of Gene Expression and Clinical Data for the Identification of Therapeutic Candidates.Comparative study of joint analysis of microarray gene expression data in survival prediction and risk assessment of breast cancer patients.Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example.Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancerObesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancerLZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistanceMELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.DACH1 suppresses breast cancer as a negative regulator of CD44.ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 lossSpectral clustering using Nyström approximation for the accurate identification of cancer molecular subtypesA multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers.A program to identify prognostic and predictive gene signaturesGenome-driven integrated classification of breast cancer validated in over 7,500 samples.A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy.Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4.Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterizationStatistical measures of transcriptional diversity capture genomic heterogeneity of cancer.Expression profiling of mitochondrial voltage-dependent anion channel-1 associated genes predicts recurrence-free survival in human carcinomasPredicting response and survival in chemotherapy-treated triple-negative breast cancer.Age-specific changes in intrinsic breast cancer subtypes: a focus on older women
P2860
Q26744071-36D3967C-D4D2-4A7C-B11F-CC6FE439DE5FQ28273187-6630544D-17D4-4099-9E6B-2E51EADAD49BQ28539113-A0976CC3-B27E-4F88-9449-AA39FFE174F5Q28730572-5BD88F5F-1600-4D05-986C-4BF97FAF3D4EQ29248638-66C7B32B-3B2D-4988-BA7E-60189679C8DDQ29248640-5181D66A-AC0F-46DC-99C7-C21601F67994Q30487036-B7A50ABE-B3A5-441A-A95A-852E950E0F2EQ30491493-67FBCE5A-1FEF-47D1-89E9-0C7DCBF558B5Q30587056-71E11435-9CD9-4B12-A5E2-C6F9999ED72CQ30707752-DDB24224-3D35-4A4F-976E-EF07751205BAQ30747169-7CC36E05-F545-41FD-98B2-F3595F391FB3Q30837398-D4921080-8BB3-4A2F-ABE6-E6CD8C303416Q30990059-E2479C43-AFC5-49BA-8336-3980BB13F405Q31011613-537CFBFA-6540-485B-92C5-AD6AEA9B0C73Q31052319-E4041AF7-0F8C-4F93-9A51-9E515985AB67Q33555064-6DBD9B40-8F9A-4604-A81C-3C6A24638EF2Q33567263-611838DA-FD85-4F59-9AF4-89DB85AC9BC3Q33572318-8FE80C98-5D9C-4924-BD9F-F7CC6FCA8791Q33630465-9DC172BD-5E0D-4B58-A107-E4C1E86DA830Q33632205-5590303C-056E-4A44-A1EC-AF2FFB76333EQ33659361-AFF6ACB6-C1FF-4DD1-864C-095DD5EC7BBEQ33692905-2AA28C23-392D-4943-A874-1F797CA4817BQ33762222-BFB5B197-9D7F-4F32-9284-59D93A979825Q33768293-DF702617-143A-4DB4-983C-FC8415382E0AQ33837764-9BA41D30-B3F9-4724-B9B4-0D6B686CF27BQ33849252-D4778739-20CF-40FD-8562-D438732944E4Q33878879-88ADCD0E-B12E-47FE-B686-90539992E748Q33884798-AC790ACF-12F2-4F66-9698-061656D30133Q33914753-FE187100-AE19-469B-B583-2CCB4644DD38Q33947907-AD2ADF04-7964-4469-9702-A47AF2DE35FCQ34077048-8FCEBB98-DB49-46B2-9C05-9E3E6D1CDE9DQ34105960-FFD194B8-BA2E-4C80-92D3-D301E39B9A90Q34199428-E295AF26-2F2F-42FD-A492-F0EFD690F83EQ34266467-5F82C42D-73D9-46ED-8056-FBE975C2CD79Q34324403-94787027-4595-45E1-8D5B-4E35D5432BA9Q34339847-F98D2D4D-062A-46FC-B910-3B22AD83C669Q34339885-0F09F24F-B21F-4E07-A420-2FDB2359EDE1Q34344405-3E523481-28A6-403C-9F0B-D2091B30CB45Q34354538-43D5EA14-C788-4E10-A6EB-44253E571D3FQ34359310-69C35895-56E7-411C-9B54-C38882C8E484
P2860
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A genomic predictor of respons ...... py for invasive breast cancer.
@en
A genomic predictor of respons ...... py for invasive breast cancer.
@nl
type
label
A genomic predictor of respons ...... py for invasive breast cancer.
@en
A genomic predictor of respons ...... py for invasive breast cancer.
@nl
prefLabel
A genomic predictor of respons ...... py for invasive breast cancer.
@en
A genomic predictor of respons ...... py for invasive breast cancer.
@nl
P2093
P2860
P50
P356
P1476
A genomic predictor of respons ...... apy for invasive breast cancer
@en
P2093
Angela DeMichele
Arlene Nazario
Daniel J Booser
Eduardo Souchon
Eleni Andreopoulou
Frankie Holmes
Gabriel N Hortobagyi
Hongkun Wang
J Ignacio Chacón
Jaime Ferrer-Lozano
P2860
P304
P356
10.1001/JAMA.2011.593
P407
P577
2011-05-01T00:00:00Z